Switching between HER2+ and HER2− is relatively common (~36%) in studies of primary vs. metastatic tumors from the same patient (85), along with IS switching—there is enrichment of HER2-E and decrease of LumA in MBC (86). The gene discussed is ERBB2; the disease is metastatic neoplasm.